Ginkgo Bioworks Holdings (DNA) Preferred Stock Liabilities (2021)

Ginkgo Bioworks Holdings (DNA) posted Preferred Stock Liabilities of $1.5 billion for Q2 2021, down 6.79% on a QoQ basis from $1.6 billion in Q1 2021.

Ginkgo Bioworks Holdings (DNA) Preferred Stock Liabilities (2021) Analysis & Trends

Ginkgo Bioworks Holdings' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $1.5 billion for Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Ginkgo Bioworks Holdings 517.16 Mn 373.30 Mn 16.38 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2021 1.47 Bn
Mar 31, 2021 1.57 Bn